<DOC>
	<DOC>NCT00788424</DOC>
	<brief_summary>This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.</brief_summary>
	<brief_title>Topical Application of AS101 for the Treatment of Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ammonium trichloro(dioxoethylene-O,O'-)tellurate</mesh_term>
	<criteria>1. Patient have a diagnosed mild to moderate stable plaque type psoriasis (less than 10% of body skin surface). 2. Patient must be 1870 years of age. 3. General health must be adequate to allow for compliance with the requirements of this protocol. 4. Patient or his/her legal guardian must sign an informed consent form prior to study participation. 5. Patient must be able and willing to comply with all protocol requirements. 1. Patients who are mentally disabled or are otherwise unable to provide fully informed consent. 2. Pregnant or breastfeeding females. 3. Patients with evidence of an infection in the targeted zones. 4. Patients with known sensitivity to any of the drug components. 5. Patients treated by systemic anti psoriatic medications within one month prior to the initial treatment with the AS101, or topical anti psoriatic preparations within two weeks prior to the initial treatment with the AS101. 6. Patient with psoriatic arthritis. 7. Patients taking immunosuppressive drugs. 8. Immunocompromised patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>AS101 Psoriasis</keyword>
</DOC>